Royalty Pharma Increases Bid for Elan
Royalty says it will pay $12.50 in cash for each share of Elan.
-
Business
Featured Story
-
Marketing & Advertising
Featured Story
IFPMA Launches 'Do You Mind?' Campaign
Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders GENEVA , May 21, 2013 /PRNewswire...
-
R&D
Featured Story
FDA, Peregrine Agree on Phase III Bavituximab Study
Peregrine rises on agreement for late-stage study WASHINGTON (AP) — Shares of Peregrine Pharmaceuticals Inc. surged Monday after the company said it...
-
Therapeutics
Featured Story
Pfizer Halts Study of Non-Hodgkin's Lymphoma Drug
An interim analysis showed the drug wasn't helping patients live longer
-
Pharmalot
Featured Story
Hopes For Autism And Fragile X Drug Dashed By Little Biotech Struggles
In a setback to autism research, a small biotech has placed its activities on hold and discontinued a clinical trial for its lead compound due to...
- Resources
- Directories
- Manny Awards
- Events
- Jobs